findinEsegui ricerca

DRI Capital

Organisation available for the Professional Exchange Call: 4 (27th Oct 2014 - 5th Dec 2014)

Type of organisation: Investment Firm


Recommended stay period: 4-6 weeks

DRI Capital

Areas of expertise looked for:

  • Patenting/IPR management
  • Investment analysis
  • Asset selection
  • Technology assessment


DRI Capital is a global leader in healthcare investing. The firm, originally called Drug Royalty Corporation, was founded in 1992 to purchase royalty streams on pharmaceutical products and to make healthcare equity investments.

In 1993, the firm was listed on the Toronto Stock Exchange and remained publicly traded until 2002 when it was purchased and taken private. In 2006, DRI Capital successfully raised $800 million ($240 million in equity and $560 million in debt) for its first managed fund, Drug Royalty I. With Drug Royalty I, DRI completed its transition to a private equity fund manager business model.

In 2010, DRI successfully raised $926 million of capital commitments ($701 million in equity for its second managed fund, Drug Royalty II, and $225 million in equity for Drug Royalty II Co-Investment Fund). As of June 30, 2013, Drug Royalty I and Drug Royalty II have collectively acquired 41 separate royalty streams from inventors, universities, research institutes, hospitals, biotechnology and global pharmaceutical companies payable on 29 different leading pharmaceutical products.

In building this portfolio, DRI led the way with numerous milestone transactions, including the first transaction outside the United States, the first transaction with an individual inventor, the first transaction on a diagnostic, the first transaction on a life science tool and the first transaction involving a bundle of royalty streams. Further, DRI's managed funds have completed more

repeat transactions with prior counterparties than any other royalty monetization firms, reinforcing DRI's leading reputation in the industry. Today DRI Capital is a fully-integrated team of 30 professionals and support staff with over $3 billion under management, focused on identifying, assessing, acquiring and managing biopharmaceutical royalty assets across the globe.

Collectively, the professional team has over 150 years of experience. The team has individuals with backgrounds in the pharmaceutical industry, as well as in scientific, financial, healthcare, intellectual property (“IP”) and legal disciplines. This breadth of knowledge and training allows DRI Capital to identify unique potential investments and conduct its due diligence on such investments quickly and effectively


This project has received funding from the European Union’s Seventh Programme for 
research, technological development and demonstration under grant agreement No 305128
  ENTENTE is supported by the European Commission and coordinated by Inserm-Transfert SA